Published in N Engl J Med on August 07, 2003
Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy (Amylo) | NCT01623245
Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy | NCT03333551
Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis | NCT04612582
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol (2011) 2.82
A causative link between the structure of aberrant protein oligomers and their toxicity. Nat Chem Biol (2010) 2.48
Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A (2010) 2.41
Updates in cardiac amyloidosis: a review. J Am Heart Assoc (2012) 2.21
Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A (2004) 2.14
Imaging cardiac amyloidosis: a pilot study using ¹⁸F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging (2014) 1.91
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood (2007) 1.83
Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood (2010) 1.76
Abeta(1-40) forms five distinct amyloid structures whose beta-sheet contents and fibril stabilities are correlated. J Mol Biol (2010) 1.74
Expanding the proteome: disordered and alternatively folded proteins. Q Rev Biophys (2011) 1.60
Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis. Kidney Int (2012) 1.45
Plasticity of amyloid fibrils. Biochemistry (2007) 1.43
Amyloid peptide channels. J Membr Biol (2004) 1.43
In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides. Proc Natl Acad Sci U S A (2011) 1.38
Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol (2008) 1.31
Al amyloidosis. Orphanet J Rare Dis (2012) 1.29
Amyloid in the cardiovascular system: a review. J Clin Pathol (2005) 1.24
Micro-imaging of amyloid in mice. Methods Enzymol (2006) 1.19
Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases. Clin J Am Soc Nephrol (2013) 1.19
Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience. Haematologica (2012) 1.19
The modulation of transthyretin tetramer stability by cysteine 10 adducts and the drug diflunisal. Direct analysis by fluorescence-detected analytical ultracentrifugation. J Biol Chem (2008) 1.16
Mysterious oligomerization of the amyloidogenic proteins. FEBS J (2010) 1.14
Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics (2008) 1.14
Comparative analysis of peptide p5 and serum amyloid P component for imaging AA amyloid in mice using dual-isotope SPECT. Mol Imaging Biol (2012) 1.13
Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol (2010) 1.10
ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol (2008) 1.08
The non-core regions of human lysozyme amyloid fibrils influence cytotoxicity. J Mol Biol (2010) 1.07
Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle. Mol Neurodegener (2009) 1.05
A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis. Blood (2014) 1.05
Current perspectives on cardiac amyloidosis. Am J Physiol Heart Circ Physiol (2011) 1.04
Characterization of the microheterogeneity of transthyretin in plasma and urine using SELDI-TOF-MS immunoassay. Proteome Sci (2004) 1.03
Mice with alopecia, osteoporosis, and systemic amyloidosis due to mutation in Zdhhc13, a gene coding for palmitoyl acyltransferase. PLoS Genet (2010) 1.02
Cellular response of cardiac fibroblasts to amyloidogenic light chains. Am J Pathol (2005) 1.02
Huntington's disease induced cardiac amyloidosis is reversed by modulating protein folding and oxidative stress pathways in the Drosophila heart. PLoS Genet (2013) 1.00
Melphalan, lenalidomide and dexamethasone for the treatment of immunoglobulin light chain amyloidosis: results of a phase II trial. Haematologica (2012) 1.00
Amyloid in endomyocardial biopsies. Virchows Arch (2010) 1.00
Preclinical development of siRNA therapeutics for AL amyloidosis. Gene Ther (2011) 0.99
Surface Induced nanofiber growth by self-assembly of a silk-elastin-like protein polymer. Langmuir (2009) 0.98
Transmission of amyloidosis in offspring of mice with AApoAII amyloidosis. Am J Pathol (2006) 0.98
On the lag phase in amyloid fibril formation. Phys Chem Chem Phys (2015) 0.98
Magnetic resonance imaging in the evaluation of non-ischemic cardiomyopathies: current applications and future perspectives. Heart Fail Rev (2006) 0.97
Ventricular fibrillation after bortezomib therapy in a patient with systemic amyloidosis. Hematol Rep (2013) 0.96
AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS One (2012) 0.96
Incidence and survival in non-hereditary amyloidosis in Sweden. BMC Public Health (2012) 0.96
Differences in immunoglobulin light chain species found in urinary exosomes in light chain amyloidosis (Al). PLoS One (2012) 0.95
Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol (2014) 0.95
Current treatment of AL amyloidosis. Haematologica (2009) 0.95
Structural mechanism of serum amyloid A-mediated inflammatory amyloidosis. Proc Natl Acad Sci U S A (2014) 0.94
HDX-ESI-MS reveals enhanced conformational dynamics of the amyloidogenic protein beta(2)-microglobulin upon release from the MHC-1. J Am Soc Mass Spectrom (2008) 0.94
Human apolipoprotein A-I natural variants: molecular mechanisms underlying amyloidogenic propensity. PLoS One (2012) 0.94
Beta2-microglobulin isoforms display an heterogeneous affinity for type I collagen. Protein Sci (2005) 0.94
Systemic amyloidosis: a challenge for the rheumatologist. Nat Rev Rheumatol (2010) 0.94
Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica (2013) 0.94
Pathophysiology and treatment of systemic amyloidosis. Nat Rev Nephrol (2013) 0.93
Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis. Haematologica (2009) 0.93
Detection of amyloid in abdominal fat pad aspirates in early amyloidosis: Role of electron microscopy and Congo red stained cell block sections. Cytojournal (2011) 0.93
Protein oxidative modifications in the ageing brain: consequence for the onset of neurodegenerative disease. Free Radic Res (2010) 0.93
The clinical features and outcomes of systemic AL amyloidosis: a cohort of 231 Chinese patients. Clin Kidney J (2014) 0.93
Utility of 18F-FDG PET(/CT) in patients with systemic and localized amyloidosis. Eur J Nucl Med Mol Imaging (2013) 0.93
Heterogeneity in primary structure, post-translational modifications, and germline gene usage of nine full-length amyloidogenic kappa1 immunoglobulin light chains. Biochemistry (2007) 0.93
Preclinical Validation of the Heparin-Reactive Peptide p5+14 as a Molecular Imaging Agent for Visceral Amyloidosis. Molecules (2015) 0.92
Lysosomal NEU1 deficiency affects amyloid precursor protein levels and amyloid-β secretion via deregulated lysosomal exocytosis. Nat Commun (2013) 0.92
Micro-heterogeneity and aggregation in beta2-microglobulin solutions: effects of temperature, pH, and conformational variant addition. Eur Biophys J (2006) 0.91
Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Res Cardiol (2013) 0.91
The reality of aging viewed from the arterial wall. Artery Res (2013) 0.91
A comparison of the biochemical modifications caused by toxic and non-toxic protein oligomers in cells. J Cell Mol Med (2011) 0.90
Plasma biomarkers of mouse aging. Age (Dordr) (2010) 0.90
Cardiac amyloidosis responding to bortezomib: case report and review of literature. Curr Cardiol Rev (2009) 0.90
α-helical structures drive early stages of self-assembly of amyloidogenic amyloid polypeptide aggregate formation in membranes. Sci Rep (2013) 0.90
Amyloidogenic peptide homologous to beta-domain region of alpha-lactalbumin. Dokl Biochem Biophys (2007) 0.89
Tau phosphorylation, aggregation, and cell toxicity. J Biomed Biotechnol (2006) 0.89
Peptide p5 binds both heparinase-sensitive glycosaminoglycans and fibrils in patient-derived AL amyloid extracts. Biochem Biophys Res Commun (2013) 0.88
Detection of populations of amyloid-like protofibrils with different physical properties. Biophys J (2010) 0.88
From bench to bedside and back again: translational research in autoinflammation. Nat Rev Rheumatol (2015) 0.87
Oligomerization and aggregation of bovine pancreatic ribonuclease A: characteristic events observed by FTIR spectroscopy. Biophys J (2006) 0.86
Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1β monoclonal antibody canakinumab. Clin Rheumatol (2014) 0.86
Dynamic PET and SPECT imaging with radioiodinated, amyloid-reactive peptide p5 in mice: a positive role for peptide dehalogenation. Peptides (2014) 0.85
A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision? Haematologica (2013) 0.85
Conjunctival amyloidosis -- clinical and histopathologic features. Graefes Arch Clin Exp Ophthalmol (2015) 0.85
Quantification of transthyretin kinetic stability in human plasma using subunit exchange. Biochemistry (2014) 0.85
Effects of a lipid environment on the fibrillogenic pathway of the N-terminal polypeptide of human apolipoprotein A-I, responsible for in vivo amyloid fibril formation. Eur Biophys J (2010) 0.85
Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. Proc Natl Acad Sci U S A (2014) 0.84
C-src enriched serum microvesicles are generated in malignant plasma cell dyscrasia. PLoS One (2013) 0.84
Cardiac amyloidosis: the great pretender. Heart Fail Rev (2015) 0.84
A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis. EMBO Mol Med (2015) 0.84
Infiltrative Cardiomyopathies. Clin Med Insights Cardiol (2015) 0.83
Rapid oligomer formation of human muscle acylphosphatase induced by heparan sulfate. Nat Struct Mol Biol (2012) 0.83
Class I major histocompatibility complex, the trojan horse for secretion of amyloidogenic β2-microglobulin. J Biol Chem (2013) 0.83
Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan. Blood (2007) 0.83
Aggregates, crystals, gels, and amyloids: intracellular and extracellular phenotypes at the crossroads of immunoglobulin physicochemical property and cell physiology. Int J Cell Biol (2013) 0.83
¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders. Clin Exp Med (2014) 0.82
Genetic structure of introduced populations: 120-year-old DNA footprint of historic introduction in an insular small mammal population. Ecol Evol (2013) 0.82
Amyloid nephropathy. Clin Kidney J (2014) 0.82
A strategy for synthesis of pathogenic human immunoglobulin free light chains in E. coli. PLoS One (2013) 0.82
The amyloidoses: clinical features, diagnosis and treatment. Methodist Debakey Cardiovasc J (2012) 0.82
Performing and processing FNA of anterior fat pad for amyloid. J Vis Exp (2010) 0.82
Targeting C-reactive protein for the treatment of cardiovascular disease. Nature (2006) 4.07
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature (2010) 1.81
The solution structure of human beta2-microglobulin reveals the prodromes of its amyloid transition. Protein Sci (2002) 1.44
Atomic structure of a nanobody-trapped domain-swapped dimer of an amyloidogenic beta2-microglobulin variant. Proc Natl Acad Sci U S A (2011) 1.38
Collagen plays an active role in the aggregation of beta2-microglobulin under physiopathological conditions of dialysis-related amyloidosis. J Biol Chem (2006) 1.33
Rapid proton-detected NMR assignment for proteins with fast magic angle spinning. J Am Chem Soc (2014) 1.29
Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N Engl J Med (2012) 1.26
The controlling roles of Trp60 and Trp95 in beta2-microglobulin function, folding and amyloid aggregation properties. J Mol Biol (2008) 1.24
Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid (2006) 1.22
Heparin strongly enhances the formation of beta2-microglobulin amyloid fibrils in the presence of type I collagen. J Biol Chem (2007) 1.18
Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics (2008) 1.14
Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum (2009) 1.10
Conformational switching and fibrillogenesis in the amyloidogenic fragment of apolipoprotein a-I. J Biol Chem (2002) 1.07
Structure, folding dynamics, and amyloidogenesis of D76N β2-microglobulin: roles of shear flow, hydrophobic surfaces, and α-crystallin. J Biol Chem (2013) 1.04
Trapping of palindromic ligands within native transthyretin prevents amyloid formation. Proc Natl Acad Sci U S A (2010) 1.02
Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proc Natl Acad Sci U S A (2009) 0.99
Properties of some variants of human beta2-microglobulin and amyloidogenesis. J Biol Chem (2003) 0.98
Molecular dynamics simulation suggests possible interaction patterns at early steps of beta2-microglobulin aggregation. Biophys J (2006) 0.96
Effect of tetracyclines on the dynamics of formation and destructuration of beta2-microglobulin amyloid fibrils. J Biol Chem (2010) 0.96
DE loop mutations affect beta2-microglobulin stability and amyloid aggregation. Biochem Biophys Res Commun (2008) 0.96
Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. Gastroenterology (2004) 0.96
DE-loop mutations affect beta2 microglobulin stability, oligomerization, and the low-pH unfolded form. Protein Sci (2010) 0.96
Native-unlike long-lived intermediates along the folding pathway of the amyloidogenic protein beta2-microglobulin revealed by real-time two-dimensional NMR. J Biol Chem (2009) 0.95
Fibrillar vs crystalline full-length beta-2-microglobulin studied by high-resolution solid-state NMR spectroscopy. J Am Chem Soc (2010) 0.94
Beta2-microglobulin isoforms display an heterogeneous affinity for type I collagen. Protein Sci (2005) 0.94
Micro-heterogeneity and aggregation in beta2-microglobulin solutions: effects of temperature, pH, and conformational variant addition. Eur Biophys J (2006) 0.91
Capillary electrophoresis studies on the aggregation process of beta-amyloid 1-42 and 1-40 peptides. Electrophoresis (2004) 0.91
Human beta-2 microglobulin W60V mutant structure: Implications for stability and amyloid aggregation. Biochem Biophys Res Commun (2009) 0.91
Lysozyme: a paradigmatic molecule for the investigation of protein structure, function and misfolding. Clin Chim Acta (2005) 0.91
Neurodegenerative diseases caused by protein aggregation: a phenomenon at the borderline between molecular evolution and ageing. Pharmacol Res (2004) 0.90
Effects of the known pathogenic mutations on the aggregation pathway of the amyloidogenic peptide of apolipoprotein A-I. J Mol Biol (2011) 0.90
Topological investigation of amyloid fibrils obtained from beta2-microglobulin. Protein Sci (2002) 0.89
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. Ann Neurol (2005) 0.89
Pharmaceutical strategies against amyloidosis: old and new drugs in targeting a "protein misfolding disease". Curr Med Chem (2004) 0.88
Proteomics of beta2-microglobulin amyloid fibrils. Biochim Biophys Acta (2005) 0.88
Structure, stability, and aggregation of β-2 microglobulin mutants: insights from a Fourier transform infrared study in solution and in the crystalline state. Biophys J (2012) 0.88
beta2-Microglobulin is potentially neurotoxic, but the blood brain barrier is likely to protect the brain from its toxicity. Nephrol Dial Transplant (2008) 0.88
The intracellular quality control system down-regulates the secretion of amyloidogenic apolipoprotein A-I variants: a possible impact on the natural history of the disease. Biochim Biophys Acta (2010) 0.87
Folding and fibrillogenesis: clues from beta2-microglobulin. J Mol Biol (2010) 0.87
Risk factors for dislocation arthropathy after Latarjet procedure: a long-term study. Int Orthop (2013) 0.87
Lysine 58-cleaved beta2-microglobulin is not detectable by 2D electrophoresis in ex vivo amyloid fibrils of two patients affected by dialysis-related amyloidosis. Protein Sci (2007) 0.85
Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis. Proc Natl Acad Sci U S A (2014) 0.84
The two tryptophans of β2-microglobulin have distinct roles in function and folding and might represent two independent responses to evolutionary pressure. BMC Evol Biol (2011) 0.84
Recombinant amyloidogenic domain of ApoA-I: analysis of its fibrillogenic potential. Biochem Biophys Res Commun (2006) 0.84
Monitoring the interaction between β2-microglobulin and the molecular chaperone αB-crystallin by NMR and mass spectrometry: αB-crystallin dissociates β2-microglobulin oligomers. J Biol Chem (2013) 0.83
Solution structure of beta(2)-microglobulin and insights into fibrillogenesis. Biochim Biophys Acta (2005) 0.83
A recurrent D-strand association interface is observed in β-2 microglobulin oligomers. FEBS J (2012) 0.83
D-strand perturbation and amyloid propensity in beta-2 microglobulin. FEBS J (2011) 0.83
Class I major histocompatibility complex, the trojan horse for secretion of amyloidogenic β2-microglobulin. J Biol Chem (2013) 0.83
Determining the energy landscape of proteins by a fast isotope exchange NMR approach. J Am Chem Soc (2012) 0.83
Molecular dynamics simulation of β₂-microglobulin in denaturing and stabilizing conditions. Proteins (2010) 0.82
Structural and folding dynamic properties of the T70N variant of human lysozyme. J Biol Chem (2003) 0.81
Structure of an early native-like intermediate of β2-microglobulin amyloidogenesis. Protein Sci (2013) 0.81
Fibrillogenesis of human β2 -microglobulin in three-dimensional silicon microstructures. J Biophotonics (2012) 0.81
Enhanced molecular chaperone activity of the small heat-shock protein alphaB-cystallin following covalent immobilization onto a solid-phase support. Biopolymers (2011) 0.80
Equilibrium unfolding thermodynamics of beta2-microglobulin analyzed through native-state H/D exchange. Biophys J (2009) 0.80
C. elegans expressing human β2-microglobulin: a novel model for studying the relationship between the molecular assembly and the toxic phenotype. PLoS One (2012) 0.80
Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis. Amyloid (2013) 0.80
Ultrastructural organization of ex vivo amyloid fibrils formed by the apolipoprotein A-I Leu174Ser variant: an atomic force microscopy study. Biochim Biophys Acta (2004) 0.80
The effects of an ideal beta-turn on beta-2 microglobulin fold stability. J Biochem (2011) 0.79
Capillary electrophoresis investigation of a partially unfolded conformation of beta(2)-microglobulin. Electrophoresis (2002) 0.79
Reduction of conformational mobility and aggregation in W60G β2-microglobulin: assessment by 15N NMR relaxation. Magn Reson Chem (2013) 0.77
Radiographic findings of femoroacetabular impingement in capoeira players. Knee Surg Sports Traumatol Arthrosc (2014) 0.77
Single-shot NMR measurement of protein unfolding landscapes. Biochim Biophys Acta (2012) 0.77
Sulfonated molecules that bind a partially structured species of beta2-microglobulin also influence refolding and fibrillogenesis. Electrophoresis (2008) 0.77
Hip resurfacing arthroplasty: mid-term results in 486 cases and current indication in our institution. Hip Int (2014) 0.76
Proteomics in protein misfolding diseases. Clin Chem Lab Med (2009) 0.76
Identification and characterization of a new ligand-binding site in FnbB, a fibronectin-binding adhesin from Streptococcus dysgalactiae. Biochim Biophys Acta (2003) 0.75
Clinical, radiological, and biochemical features of a bilateral buttock amyloidoma emerging after 27 years of hemodialysis. Amyloid (2009) 0.75
Embryonic stem and haematopoietic progenitor cells resist to Aβ oligomer toxicity and maintain the differentiation potency in culture. Amyloid (2010) 0.75
Search of ligands for the amyloidogenic protein beta2-microglobulin by capillary electrophoresis and other techniques. Electrophoresis (2005) 0.75
Pathological self-aggregation of β(2)-microglobulin: a challenge for protein biophysics. Subcell Biochem (2012) 0.75
Preliminary crystallographic characterization of the human beta2 microglobulin His31Tyr mutant in a tetrameric assembly. Acta Crystallogr D Biol Crystallogr (2003) 0.75